Ashton Thomas Private Wealth’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ashton Thomas Private Wealth’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.9K	Hold	400	–	–	﹤0.01%	1394
2026 Q1	$31.7K	Buy	+400	New	+$32.3K	﹤0.01%	1318
2024 Q3	–	Sell	-400	Closed	-$25.9K	–	1461
2024 Q2	$25.9K	Buy	+400	New	+$25.3K	﹤0.01%	1087

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Ashton Thomas Private Wealth's PBE Position: Q2 2026 in Review

Ashton Thomas Private Wealth held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2026 at 400 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1394.

Ashton Thomas Private Wealth first reported a position in PBE in Q2 2024 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

Ashton Thomas Private Wealth held 400 shares of Invesco Biotechnology & Genome ETF worth $35.9K as of Q2 2026.
Ashton Thomas Private Wealth left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q2 2026, its #1394 holding.
Ashton Thomas Private Wealth first reported a position in Invesco Biotechnology & Genome ETF in Q2 2024 and has held it in 3 quarters since.
105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.